Introduction
Significant advances in the treatment of rheumatoid arthritis (RA) have been made during the past decade. The introduction of tumour necrosis factor (TNF) inhibitor therapy has been highly effective, and has led not only to improvements in the signs and symptoms of disease and the inhibition of the progression of joint damage, but also to improvement in patient-centred outcomes, such as physical function, pain and fatigue. 1 The inclusion of patientreported outcomes in clinical trials is becoming increasingly important from both the patients' and physicians' perspectives, and patients now want more information and a greater focus on the measurement of patient-centred outcomes. 2,3 P Taylor, B Manger, J Alvaro-Gracia et al.
Pain management in rheumatoid arthritis
Previous studies have shown that patients and physicians may have differing views on the major goals of RA treatment. For example, most physicians view optimized suppression of synovitis as a major treatment goal; when achieved and sustained, this may result in inhibition of structural damage, improved physical function, reduced comorbidities and, in some cases, remission. 1 Patients' perceptions regarding treatment goals, specifically those of preventing disability, pain and psychological symptoms, can differ from those of clinicians. 4 -6 Indeed, differences in patients' and clinicians' perceptions regarding physical and psychological wellbeing in RA and other chronic conditions have been reported. 7 -9 Thus, a survey was conducted to identify the key areas of health and aspects of disease management that need improvement from the patients' perspective. The DEveloping SuperIor UnderstandinG of RA Patients' Needs (DESIGN) survey was conducted among RA patients in Europe and the USA. The authors have deemed the findings to be of particular significance and importance to the RA community, lending valuable insights into patients' perspectives regarding effective pain management and areas for improved patient care. The results pertaining specifically to pain management are reported here.
Patients and methods PATIENTS
Adult patients with self-reported RA from Europe and the USA were recruited via physician referral, patient associations, the internet, patient databases and word of mouth. Patients were eligible for the survey if they responded positively to questions indicating they were aged ≥ 18 years, were formally diagnosed with RA by a physician and were currently under the care of a rheumatologist. Additionally, in Europe, patients were eligible if they reported that they had seen a rheumatologist at least once in the past 12 months (or previous 24 months in the UK). The European survey was conducted between October and November 2007, and the US survey was conducted between January and February 2007.
SURVEY AND DATA COLLECTION
Data collection was performed via a survey administered to eligible participants. In Europe (UK, France, Germany, Spain and Italy), the patient survey was translated into the native language of each respective country and conducted via a 45 -60-min structured face-to-face interview. In the USA, the 45-min survey was conducted via the internet or via a mailed paper survey. The European study was originally conducted separately from the US study; thus, some elements of the questionnaire, such as questions on fatigue, do not correspond between the studies.
Questions covered patient demographics, disease status, disease knowledge and severity, rheumatologist visits and relationship, treatments, emotions, and attitudes and behaviours related to RA. Responses were measured on seven-and fivepoint Likert scales and by asking patients to 'select all that apply' and to list ranking. To assess their disease status, respondents were asked a series of general questions concerning how they would describe the severity of their RA in the past 60 days (mild, moderate, or severe) and the current activity level of their RA over the last 2 months (active -currently experiencing persistent symptoms or flares; or inactive/in remission -has not experienced any symptoms for at least 2 months, including fatigue, joint pain, morning stiffness lasting longer than 15 P Taylor, B Manger, J Alvaro-Gracia et al. Pain management in rheumatoid arthritis min, tender joints, or swollen joints). Patients were also asked how well their RA had been controlled in the previous 2 months (not at all controlled, poorly controlled, somewhat controlled, well controlled, or completely controlled).
To evaluate patients' perceptions regarding pain, participants were asked to rate their level of pain (mild -I am able to carry out my usual daily activities without my pain interfering; moderate -I am able to carry out my usual daily activities, but am sometimes limited by what I can do because of the pain; or severe -I am unable to carry out most of my usual daily activities because of my pain). Respondents also rated their level of dissatisfaction with pain as well as other health areas and their overall satisfaction with current biologic medication in terms of how well it helped them to manage their pain.
STATISTICAL ANALYSIS
Clearly defined sampling quotas were used to obtain and ensure a representative sample and to prevent a potential internet user population bias of patient distribution by age, gender, disease severity, RA medication and use of biologic therapy.
In Europe, a recruitment goal of 500 patients was based on obtaining a similar demographic distribution sample as in the preparation of a report in May 2006 by Decision Resources Inc. (Immune and Inflammatory Disorders Study No. 3: Rheumatoid Arthritis. Waltham, MA: Decision Resources Inc., unpublished). Thresholds for the number of respondents per demographic category were established: age distribution (57% aged ≥ 65 years, 18% aged 56 -64 years, 22% aged 41 -55 years and 3% aged ≤ 40 years); gender (73% female); disease severity (24% mild RA, 76% moderate-tosevere RA); current RA treatment with a prescription (95%); and current biologic use (20 -25%). To reflect overall European trends accurately, the European patient data were weighted according to the age and gender structure of the individual countries (UK 26%, France 16%, Germany 35%, Spain 10%, Italy 13%).
In the USA, a goal of recruiting 2000 patients was established to ensure an adequate statistical distribution as determined by the baseline demographic results from two large RA registry trials (Rheumatoid Arthritis Disease-modifying Antirheumatic Drug Intervention and Utilization Study; RADIUS I and II). 10, 11 Thresholds for the number of respondents per demographic category were also established: age distribution (12 -20% aged ≥ 65 years, 25 -30% aged 56 -64 years, 30 -35% aged 41 -55 years, 10 -20% aged ≤ 40 years); gender (70 -75% female); disease severity (20 -30% mild RA, 70 -80% moderate-to-severe RA); current RA treatment with a prescription (93 -97%); and current biologic use (30 -35%).
The survey analysed question responses from Likert scales designed for five to seven attitudinal domains. Ordered logistic regression on Likert scales was used to identify demographic, symptom and attitudinal trends concerning questions related to pain and fatigue. Data from the Likert scales were further assessed by reducing responses to the nominal level by combining all agree and disagree responses into categories of 'accept' and 'reject'; relationships between self-reported levels of pain and fatigue were then assessed for significance using Pearson's χ 2 analysis. The χ 2 and z tests were used when comparing the proportion of respondents' answers to questions measuring satisfaction with pain, control of arthritis and severity of disease (e.g. percentage of patients who rated Pain management in rheumatoid arthritis response as 5 -7 on the 1 -7 Likert scale, percentage reporting well-controlled arthritis and percentage reporting severe pain). Statistical analysis of data was undertaken with Excel (Microsoft Corp., Redmond, VA, USA). A P-value < 0.01 was considered to be statistically significant.
Results
A total of 2795 adult patients with selfreported RA from Europe (756 patients) and the USA (2039 patients) were included via physician referral, patient associations, the internet, patient databases and word of mouth. Of the 756 respondents from Europe who completed the interviews, 154 were from the UK, 150 from France, 150 from Germany, 150 from Spain and 152 from Italy. Of the 2039 US respondents, 91% (1852) completed the survey via the internet and 9% (187) via a mailed paper survey; respondents represented three regions of the USA: 44% (897) eastern; 41% (836) mid-west; 13% (265) western; and 2% (41) unknown. Demographic and clinical characteristics of the patients from Europe and the USA are presented in Table 1 .
In Europe, 75% (570) of all participants reported taking at least one diseasemodifying antirheumatic drug (DMARD) and 24% (178) reported taking a biologic for the treatment of RA. In the USA, 69% (1398) of all participants reported currently taking at least one DMARD and 34% (700) reported taking a biologic. Approximately 15% and 27% of participants reported taking antidepressants in Europe and the USA, respectively.
Patients were asked to rate how well their RA had been controlled in the past 2 months in terms of managing symptoms, with responses ranging from 'not at all controlled' to 'completely controlled'. The majority of patients in both Europe (87%) and the USA (85%) reported their RA as being somewhatto-completely controlled, while only 12% in Europe and 15% in the USA reported not at all controlled or poorly controlled. Interestingly, of those patients who rated their RA as somewhat-to-completely controlled, 75% of European and 82% of US patients reported their pain level as being moderate-to-severe in the previous 2 months.
As expected, patients with all levels of RA severity reported pain, the level of pain (mild, moderate, or severe) corresponding with reported RA severity (Fig. 1) . The majority of European and US patients (60% and 65%, respectively) reported dissatisfaction with their arthritis pain (rating 1 -3 on the seven-point Likert scale) compared with those who were satisfied (Europe 29%, USA 23%, rating 5 -7 on the seven-point Likert scale) or neutral (Europe 10%, USA 12%, rating 4 on the seven-point Likert scale) with their arthritis pain (Fig. 2 ). Patient satisfaction with arthritis pain was significantly correlated with satisfaction with other areas of health. Patients who were satisfied with their level of pain were more likely to have higher satisfaction with their level of social activity, tension, mood and fatigue: P < 0.01 satisfaction with pain versus social activity (Pearson correlation coefficients: Europe 0.53, USA 0.57); level of tension (Europe 0.51, USA 0.62); mood (Europe 0.45, USA 0.59); and fatigue (Europe 0.54, US data not available). In addition, pain severity was directly related to the level of fatigue in both Europe and the USA (Fig.  3) , with similar overall levels of fatigue reported in Europe (34% mild, 47% moderate, 19% severe) and in the USA (21% mild, 64% moderate, 15% severe).
Higher percentages of European and US patients with severe pain reported being treated for depression (i.e. receiving interventions other than or in addition to Pain management in rheumatoid arthritis prescription antidepressants) (Europe 22%, USA 41%) than those with moderate (Europe 15%, USA 26%) or mild pain (Europe 7%, USA 15%). A higher percentage of patients with severe pain reported using antidepressants. In Europe, 6%, 17% and 23% of those reporting mild, moderate and severe pain, respectively, were taking antidepressants and, in the USA the percentages were 14%, 27% and 43%, respectively. Overall, 67% of European patients who reported taking antidepressants felt that their depression was linked to their RA.
When participants in Europe and the USA were asked to rate their level of agreement with statements gauging their worries and fears about the future, more than one-third of European participants (37%) and more than half of US participants (52%) (9) Data are presented as mean ± SD or n (%). Percentages may not total 100% because of rounding. a Proportion of all participants who reported taking at least one disease-modifying antirheumatic drug (DMARD). Some participants reported taking more than one DMARD. Pain management in rheumatoid arthritis agreed/strongly agreed (rating 6 -7 on the seven-point Likert scale) with the statement 'I'm worried that one day my medicine will not be strong enough to control my pain', and 31% of European and 39% of US participants agreed/strongly agreed with the statement 'I feel like my life is generally going to be filled with pain because of my RA'. Patients who agreed/strongly agreed with these two statements were stratified according to pain severity (mild, moderate, or severe) to determine the relationship between pain and future concerns.
Participants with severe pain reported significantly greater worries and fears compared with those with moderate or mild pain. For example, 62% (Europe) and 75% (USA) of participants with severe pain worried about a future life filled with pain compared with those with moderate (Europe 29%; USA 39%) or mild pain (Europe 14%; USA 13%) (P < 0.01 for all comparisons). In addition, those with mild pain were more optimistic than those with moderate or severe pain with regard to living a 'normal' life (rating 6 -7 on the seven-point Likert (Fig. 4) .
In the USA, 44% of patients rated pain relief as the top benefit desired from their RA medication. Of the users of biologics in Europe (n = 179) and the USA (n = 700), the majority (92% and 81%, respectively) were 'somewhat satisfied' to 'extremely satisfied' (ranking 6 -7 on the seven-point Likert scale) with their biologic therapy. Of the patients who were satisfied with their biologic therapy, pain relief was the most common reason for satisfaction and ranked number one by 47% and 27% of European and USA patients, respectively. Second ranked reasons for satisfaction were 'it makes me feel better overall and enjoy life more' (Europe) and 'it should slow down joint damage' (USA). Additionally, of patients with severe RA who were current biologic users, 42% (Europe) and 56% (USA) reported they were 'extremely dissatisfied' to 'dissatisfied' (ranking 1 -2 on the sevenpoint Likert scale) with their pain, which was significantly lower compared with those not currently taking a biologic (Europe 67%; USA 75%; P < 0.01) (Fig. 5) . The percentage of patients reporting high satisfaction with their level of pain (rating 6 -7 on the sevenpoint Likert scale) was low in both the biologic user and the biologic non-user groups (Europe 10% versus 3.8%; USA 3.9% versus 1.5%).
Discussion
Pain is a prominent symptom in patients with RA. It is a personal and subjective burden of disease that greatly impacts patients' overall sense of well-being. Patients' perspectives of their disease and treatment are now being used to determine treatment effectiveness and effectiveness of disease assessment measures. 12, 13 Patientcentred measures used in clinical trials and in daily practice are seen as tools to capture the relative importance of patient priorities, the emphasis of which may change with disease status, duration or progression. 14 This survey quantitatively investigated the subjective experiences of a large number of patients (2795) in Europe and the USA, focusing on pain and its ancillary effects as a burden of disease. After reviewing the literature for other accounts of subjective patient reports, the authors believe this to be An increased awareness of patients' perspectives and preferences for treatment outcomes may help clinicians provide more effective and efficient patient care. 15, 16 A study similar to the currently reported DESIGN survey previously examined preferences for improvement in RA treatment and reported that pain is the area in which the majority of patients would like to see an improvement in their RA management. 17 In the same study, the authors argued that a patient-centred approach is essential in assessing treatment needs and that without this approach there may be 'ignorance of key symptoms and issues preferred by patients'. Patient preferences have been implemented in some of the instruments used for measuring broad areas of function such as physical disability. 18, 19 There are, however, few studies that report RA patients' perspectives on improvement in multiple areas of health outcomes.
The present study indicated that RA 
Moderate fatigue
Severe fatigue Pain management in rheumatoid arthritis patients in both Europe and the USA are dissatisfied with their levels of pain, with an overwhelming majority (75% and 82%, respectively) who rated their RA as somewhat-to-completely controlled reporting moderate-to-severe pain in the previous 2 months, further confirming that more effective pain management is needed for patients with RA. In reviewing other subjective patient reports, it has been reported that approximately 70% of RA patients would like to see an improvement in their pain management. 17 Huyser et al. 20 suggested that pain, depressive symptoms and fatigue form an inter-related matrix of RA symptoms that are relatively independent of RA disease activity. Results from the currently reported DESIGN survey further corroborate the inter-related matrix of RA symptoms, as significant correlations between the level of pain, and tension, mood and fatigue were observed.
Previous reports have shown that high levels of pain can be associated with negative ancillary effects, such as lack of sleep, depression, psychological distress and worry. 21, 22 It was found that the majority of patients with severe pain (62% in Europe and 75% in the USA) were worried that their future life would be filled with pain because B -USA Pain management in rheumatoid arthritis of RA. Furthermore, 22% and 41% of European and US participants with severe pain, respectively, reported being treated for depression, supporting previous reports of the association between pain, depression and other negative ancillary effects. 21, 22 Aside from pain associated with disease and ancillary burdens, pain is a component factored into choice for RA therapies. Although a majority of European and US patients (92% and 81%, respectively) in the survey expressed satisfaction with their biologic therapy, less than half of the patients cited relief from pain as the reason for their satisfaction, suggesting that, despite treatment, more effective pain relief is required. In previous studies of prioritizing outcomes, 65 -69% of RA patients reported pain as their treatment priority using the Arthritis Impact Measurement Scale 2 (AIMS2), 14, 17 and, in another study, 36% of patients selected pain as one of their top three most important treatment outcomes. 23 In accordance with these reports, the present study showed that nearly half of the US patients (44%) selected relief from pain as the top benefit desired from RA therapy.
A potential limitation of the survey was that it used subjective questionnaires rather than validated instruments to assess patients' perceptions. Two commonly utilized methods of psychosocial measurement are the Likert scale and the visual analogue scale (VAS). This survey used the former rather than validated measures such as a VAS for pain or the Health Assessment Questionnaire, which are commonly used for assessing RA in the context of clinical trials and routine practice. 24 Although this limits the ability to compare the data from the present study with other similar patient groups, self-report questionnaires have been used as valid assessment tools for many years and provide substantial insight into the subjective experience of coping with the daily burden of disease that may not otherwise be recognized. 24, 25 Data gathered from such questionnaires may also lead to the development of additional, validated measures that may be used in the future. Thus, the limitations of a non-validated, subjective survey should not detract from the valuable insights gained concerning patients' perspectives in effective pain management. Finally, the survey in Europe was conducted via face-to-face interviews, which may have introduced a bias to the responses, and cultural differences among different European countries were not captured in the survey.
In conclusion, the results from the present survey demonstrate that, despite treatment, levels of pain remain high among patients with RA and that two-thirds of patients are dissatisfied with their level of pain. The vast majority of patients feel that their RA is somewhat-to-well controlled; however, three-quarters of patients still report experiencing moderate-to-severe pain. Additionally, the relationship between pain and negative ancillary burdens, such as fatigue and depression, further emphasizes the farreaching consequences of ineffective pain management. These observations highlight pain as an under-treated burden of disease despite RA therapy and underscore the case for a comprehensive examination of patients' perspectives regarding effective pain management in RA to improve patient care and long-term outcomes.
